rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RPRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Here's How Much $100 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today
      Nov 13BenzingaRPRX
      Royalty Pharma: Stronger Royalty Growth Supports Further Upside
      Nov 12Seeking AlphaRPRX
      Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
      Nov 8Yahoo FinanceRPRX
      How Investors Are Reacting To Royalty Pharma (RPRX) Earnings Beat
      Nov 6Yahoo FinanceRPRX
      Royalty Pharma (RPRX) Stock Looks Fully Valued After A 168% Run
      Nov 6Yahoo FinanceRPRX
      Can Royalty Pharma (RPRX) Justify Its Price Following A Third Straight Guidance Raise?
      Nov 6Yahoo FinanceRPRX
      Royalty Pharma PLC (RPRX) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong Royalty ...
      Nov 5Yahoo FinanceRPRX
      Royalty Pharma plc Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceRPRX
      Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play (NASDAQ:RPRX)

      Royalty Pharma plc offers defensive biopharma growth, high returns, and portfolio diversification. Click to read the RPRX investment case now.

      Nov 4Seeking AlphaRPRX
      Royalty Pharma Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceRPRX
      Royalty Pharma Q3 2026 slides: guidance raised, new royalties acquired
      Nov 4Investing.comRPRX
      Earnings call transcript: Royalty Pharma tops Q3 2026 estimates, shares slip
      Nov 4Investing.comRPRX
      Royalty Pharma earnings beat by $0.03, revenue topped estimates
      Nov 4Investing.comRPRX
      Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics
      Nov 4Yahoo FinanceRPRX
      Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
      Nov 4Yahoo FinanceRPRX
      Royalty Pharma: Q3 Earnings Snapshot

      NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported third-quarter earnings of $145 million.The New York-based company said it had profit of 26 cents per share.

      Nov 4Yahoo FinanceRPRX
      Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today
      Nov 3BenzingaRPRX
      Royalty Pharma earnings in focus as pelacarsen weighs
      Nov 3Investing.comRPRX
      Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
      Oct 30Yahoo FinanceRPRX
      Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
      Oct 28Yahoo FinanceRPRX
      Royalty Pharma stock reaches all-time high at 64.42 USD
      Oct 26Investing.comRPRX
      Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead | The Motley Fool

      Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development.

      Oct 25The Motley FoolRPRX
      Missed Royalty Pharma's Rally? Here's The Case Holders Backed

      Royalty Pharma kept printing upbeat headlines, with recurring royalty receipts rising and new late stage deals like cliramitug and rusfertide added to the portfolio, even as one quarterly net margin compressed from 5.6% to 2.7%. For Royalty Pharma shareholders, the return over the past year was 74.7%, including dividends. If you had been weighing the bullish growth story against debt, pricing pressure, and pipeline risk in October 2025, what made that trade off worth accepting? The useful...

      Oct 24Yahoo FinanceRPRX
      Royalty Pharma declares $0.235 Q4 dividend, payable Dec. 10
      Oct 16Investing.comRPRX
      If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
      Oct 15BenzingaRPRX
      Royalty Pharma (RPRX) Offers Attractive Risk-Reward Profiles at Reasonable Multiples
      Oct 12Yahoo FinanceRPRX
      Royalty Pharma EVP Marshall Urist sells $235,594 in shares
      Oct 12Investing.comRPRX
      Bank of America Securities Remains a Buy on Royalty Pharma (RPRX)

      Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailRPRX
      ABS Frontiers: Royalty-Backed Securitization Is A Shot In The Arm For Pharma Funding
      Oct 9S&P GlobalRPRX
      Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
      Oct 8Yahoo FinanceRPRX
      Royalty Pharma (RPRX) Gets a Buy from Morgan Stanley

      Tipranks Press Release.

      Oct 8The Globe and MailRPRX
      Royalty Pharma EVP Marshall Urist sells $238,812 in shares
      Sep 30Investing.comRPRX
      If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Royalty Pharm

      Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of

      Sep 29BenzingaRPRX
      Royalty Pharma EVP Christopher Hite sells $5.85m in shares
      Sep 25Investing.comRPRX
      Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
      Sep 25NasdaqRPRX
      Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? | The Motley Fool

      Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

      Sep 25The Motley FoolRPRXRVMD
      Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
      Sep 24Yahoo FinanceRPRX
      Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks
      Sep 23Investing.comRPRXBAC
      Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run

      Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...

      Sep 23Yahoo FinanceRPRX
      Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
      Sep 23Yahoo FinanceRPRX
      Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program

      Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.

      Sep 15Yahoo FinanceRPRX
      Royalty Pharma at Morgan Stanley conference: growth broadens beyond royalties
      Sep 14Investing.comRPRXMS
      Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

      Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]

      Sep 10Yahoo FinanceRPRX
      Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailRPRXSMMT
      Royalty Pharma to present at upcoming investor conferences

      NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDTBofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com

      Sep 9Yahoo FinanceRPRX
      If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
      Sep 8BenzingaRPRX
      TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook
      Sep 8Investing.comRPRX
      Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial

      Royalty Pharma (RPRX) shares fell nearly 6% in Tuesday trading after Novartis' (NVS) experimental he

      Sep 8Yahoo FinanceRPRX
      Royalty Pharma expects modest return despite pelacarsen trial failure
      Sep 4Investing.comRPRX
      Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma
      Sep 2Seeking AlphaRPRXTEVA

      This is the newest page. Registered accounts read further back.